natgillin/translations-raw huggingface dataset:
The efficacy of sofosbuvir was evaluated in five Phase 3 studies in a total of 1,568 adult patients with genotypes 1 to 6 chronic hepatitis C. One study was conducted in treatment-naïve patients with genotype 1, 4, 5 or 6 chronic hepatitis C in combination with peginterferon alfa 2a and ribavirin and the other four studies were conducted in patients with genotype 2 or 3 chronic hepatitis C in combination with ribavirin including one in treatment-naïve patients, one in interferon intolerant, ineligible or unwilling patients, one in patients previously treated with an interferon-based regimen, and one in all patients irrespective of prior treatment history or ability to receive treatment with interferon. 
Jedno je ispitivanje bilo provedeno u kombinaciji s peginterferonom alfa 2a i ribavirinom u bolesnika koji prethodno nisu bili liječeni i imali su kronični hepatitis C uzrokovan genotipovima 1, 4, 5 ili 6, dok su ostala četiri ispitivanja bila provedena u kombinaciji s ribavirinom u bolesnika s kroničnim hepatitisom C uzrokovanim genotipovima 2 ili 3 uključujući jedno u bolesnika koji prethodno nisu bili liječeni, jedno u bolesnika koji nisu podnosili interferon, nisu bili pogodni za liječenje interferonom ili nisu dali pristanak za liječenje interferonom, jedno u bolesnika prethodno liječenih režimom na bazi interferona i jedno u svih bolesnika bez obzira na prethodno liječenje ili sposobnost primanja liječenja interferonom.
Study 4063 was an open-label study that evaluated a fixed dose combination of sofosbuvir and ledipasvir in 95 patients with HCV-infection and ESRD requiring dialysis. 
Ispitivanje 4063 bilo je otvoreno ispitivanje u kojem je procijenjena fiksna kombinacija sofosbuvira i ledipasvira u 95 bolesnika s infekcijom HCV­om s ESRD­om koji je zahtijevao dijalizu.
Otherb a. The denominator for relapse is the number of patients with HCV RNA <LLOQ at their last on-treatment assessment. 
Nazivnik za relaps je broj bolesnika s HCV RNK < LLOQ na njihovom posljednjem pregledu za vrijeme trajanja terapije.
Patients with genotype 1, 4, 5 or 6 CHC 
Bolesnici s CHC­om uzrokovanim genotipom 1, 4, 5 ili 6
Cirrhotic 
Ciklosporin
Discontinuation of dosing in adults and adolescents If the other medicinal products used in combination with Sovaldi are permanently discontinued, Sovaldi should also be discontinued (see section 4.4). 
Ako se trajno prekine primjena drugih lijekova u kombinaciji sa Sovaldijem, potrebno je također prekinuti primjenu Sovaldija (vidjeti dio 4.4).
Table 16: SVR12 rates for selected subgroups by genotype in study VALENCE 
Tablica 16: Stope SVR12 za odabrane podskupine prema genotipu u ispitivanju VALENCE Genotip 2
• headache 
● glavobolja
Cirrhosis No 
Ciroza Ne
The frequency of the following side effects is not known (frequency cannot be estimated from the available data). 
Učestalost sljedećih nuspojava nije poznata (učestalost se ne može procijeniti iz dostupnih podataka): - široko rasprostranjen, težak osip kod kojeg se koža guli i koji može biti popraćen vrućicom,
You may need closer monitoring of your blood glucose levels and/or adjustment of your diabetes medication after starting Sovaldi. 
Nakon što počnete uzimati lijek Sovaldi, možda ćete trebati pažljivije pratiti razinu glukoze u krvi i/ili prilagoditi lijek protiv šećerne bolesti.
Co-administration with such medicinal products is not recommended with Sovaldi (see section 4.4). 
Ne preporučuje se istodobna primjena takvih lijekova sa Sovaldijem (vidjeti dio 4.4).
Sofosbuvir ↑ Cmax 1.45 (1.10, 1.92) ↑ AUC 1.34 (1.12, 1.59) Cmin (NA) 
↑ Cmax 1,45 (1,10; 1,92) ↑ AUC 1,34 (1,12; 1,59) Cmin (ND/NP)
Common arthralgia, back pain, muscle spasms, myalgia back pain, muscle spasms 
Često artralgija, bol u leđima, mišićni grčevi, mialgija bol u leđima, mišićni grčevi
The safety profile of sofosbuvir and ribavirin in liver transplant adult recipients with chronic hepatitis C was similar to that observed in patients treated with sofosbuvir and ribavirin in Phase 3 clinical studies (see section 5.1). 
Sigurnosni profil sofosbuvira i ribavirina u odraslih bolesnika s kroničnim hepatitisom C kojima je transplantirana jetra bio je sličan onome opaženom u bolesnika liječenih sofosbuvirom i ribavirinom u kliničkim ispitivanjima faze 3 (vidjeti dio 5.1).
• feeling tired and irritable 
● umor i razdražljivost
Tell your doctor if you have kidney problems or if you are on kidney dialysis. 
Tegobe s bubrezima Obavijestite liječnika ako imate tegobe s bubrezima ili se liječite dijalizom bubrega.
Interferon intolerant, ineligible or unwilling (POSITRON) 
Bolesnici koji nisu podnosili interferon, nisu bili pogodni za liječenje interferonom ili nisu dali pristanak za liječenje interferonom (POSITRON)
Sofosbuvir ↓ Cmax 0.52 (0.43, 0.62) ↓ AUC 0.52 (0.46, 0.59) Cmin (NA) 
↓ Cmax 0,52 (0,43; 0,62) ↓ AUC 0,52 (0,46; 0,59) Cmin (NA)
IMMUNOSUPPRESSANTS Ciclosporine (600 mg single dose) 
Ciklosporine (jedna doza od 600 mg)
Treatment-experienced 90% (37/41) Non-cirrhotic 
Bolesnici koji prethodno nisu bili liječeni 97% (31/32) Bez ciroze
Otherc a. The efficacy analysis includes 6 patients with recombinant genotype 2/1 HCV infection. 
Analiza djelotvornosti uključuje 6 bolesnika s infekcijom rekombinantnim genotipom 2/1 HCV­a.
HCV genotype 2 
genotip 2 HCV­a genotip 3 HCV­a
Table 23: Outcomes by therapeutic regimen and treatment duration, a comparison across studies in genotype 4, 5 and 6 HCV infection 
Tablica 23: Ishodi prema terapijskom režimu i trajanju liječenja, usporedba ispitivanja za infekciju genotipom 4, 5 i 6 HCV­a
The safety profile of sofosbuvir and ribavirin in HCV infected adult patients prior to liver transplantation was similar to that observed in patients treated with sofosbuvir and ribavirin in Phase 3 clinical studies (see section 5.1). 
Sigurnosni profil sofosbuvira i ribavirina kod odraslih bolesnika zaraženih HCV­om prije transplantacije jetre bio je sličan onome opaženom u bolesnika liječenih sofosbuvirom i ribavirinom u kliničkim ispitivanjima faze 3 (vidjeti dio 5.1).
Hepatic impairment 
Nesanica nesanica
AUC, Cmax, Cmina,b 
Srednja vrijednost omjera (90% interval pouzdanosti) za AUC, Cmax, Cmina,b
The safety profile of sofosbuvir and ribavirin in HCV/HIV co-infected adult patients was similar to that observed in mono-infected HCV patients treated with sofosbuvir and ribavirin in Phase 3 clinical studies (see section 5.1). 
Sigurnosni profil sofosbuvira i ribavirina kod odraslih bolesnika istodobno zaraženih HCV/HIV­om bio je sličan onome opaženom kod bolesnika zaraženih samo HCV­om koji su bili liječeni sofosbuvirom i ribavirinom u kliničkim ispitivanjima faze 3 (vidjeti dio 5.1).
Patients with genotype 3 CHC 
Bolesnici s CHC­om uzrokovanim genotipom 3
Metabolism and nutrition disorders: Very common decreased appetite 
Poremećaji metabolizma i prehrane:
The SVR rates for the 8, 12, and 24 week ledipasvir/sofosbuvir treatment groups were 93% (42/45), 100% (31/31), and 79% (15/19), respectively. 
Stope SVR­a u skupinama koje su liječene ledipasvirom/sofosbuvirom 8, 12 odnosno 24 tjedna bile su 93% (42/45),
Table 14: SVR12 rates for selected subgroups by genotype in study FUSION 
Tablica 14: Stope SVR12 za odabrane podskupine prema genotipu u ispitivanju FUSION Genotip 2
Genotype Genotype 1 
Genotip 1
Table 16 presents the subgroup analysis by genotype for cirrhosis and exposure to prior HCV treatment. 
Tablica 16 prikazuje analizu prisutnosti ciroze i prethodne izloženosti liječenju HCV­a u podskupinama prema genotipu.
b. Consideration should be given to potentially extending the duration of therapy beyond 12 weeks and up to 24 weeks; especially for those subgroups who have one or more factors historically associated with lower response rates to interferon-based therapies (e.g. advanced fibrosis/cirrhosis, high baseline viral concentrations, black race, IL28B non CC genotype, prior null response to peginterferon alfa and ribavirin therapy). 
Potrebno je razmotriti mogućnost produljenja trajanja terapije na više od 12 tjedana do najviše 24 tjedna, osobito u podskupina s jednim ili više čimbenika koji se otprije povezuju s nižim stopama odgovora na terapiju na bazi interferona (npr. uznapredovala fibroza/ciroza, visoke početne koncentracije virusa, crna rasa, ne-CC genotip IL28B, prethodni izostanak odgovora na terapiju peginterferonom alfa i ribavirinom).
No dose adjustment of sofosbuvir or ciclosporin is required at initiation of co-administration. 
Nije potrebna prilagodba doze sofosbuvira ili ciklosporina na početku istodobne primjene.
Otherc a. The efficacy analysis includes 3 patients with recombinant genotype 2/1 HCV infection. 
Analiza djelotvornosti uključuje 3 bolesnika s infekcijom rekombinantnim genotipom 2/1 HCV­a.
SOF+PEG+RBV 12 weeks 
SOF+PEG+RBV 12 tjedana
Severe RI (eGFR <30 mL/min/1.7 3m2) 
Teško oštećenje bubrega (eGFR < 30 ml/min/ 1,73 m2)
Patients with genotype 2 CHC 
Bolesnici s CHC­om uzorkovanim genotipom 2
Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. 
Rizik od simptomatske bradikardije kod istodobne primjene amiodarona može biti povećan u bolesnika koji također uzimaju beta blokatore ili u onih s istodobno prisutnom osnovnom srčanom bolešću i/ili uznapredovalom bolešću jetre.
Consideration should be given to treating these patients, and potentially extending the duration of therapy with sofosbuvir, peginterferon alfa and ribavirin beyond 12 weeks and up to 24 weeks; especially for those subgroups who have one or more factors historically associated with lower response rates to interferon-based therapies (advanced fibrosis/cirrhosis, high baseline viral concentrations, black race, IL28B non CC genotype). 
Potrebno je razmotriti liječenje tih bolesnika i mogućnost produljenja trajanja terapije sofosbuvirom, peginterferonom alfa i ribavirinom na više od 12 tjedana do najviše 24 tjedna, osobito u podskupina s jednim ili više čimbenika koji se otprije povezuju s nižim stopama odgovora na terapiju temeljenu na interferonu (uznapredovala fibroza/ciroza, visoke početne koncetracije virusa, crna rasa, ne­CC genotip IL28B).
Table 14 presents the subgroup analysis by genotype for cirrhosis and response to prior HCV treatment. 
Tablica 14 prikazuje analizu prisutnosti ciroze i odgovora na prethodno liječenje HCV­a u podskupinama prema genotipu.
Cases of severe bradycardia and heart block have been observed when sofosbuvir containing-regimes are used in combination with amiodarone and/or other medicinal products that lower heart rate (see sections 4.4 and 4.5). 
Slučajevi teške bradikardije i srčanog bloka uočeni su kada su se režimi koji sadrže sofosbuvir koristili u kombinaciji s amiodaronom i/ili drugim lijekovima koji snižavaju srčanu frekvenciju
SOF+RBV 24 weeks (n = 250) 
SOF+RBV 24 tjedna (n = 250)
SOF+RBV 24 weeks 
SOF+RBV 24 tjedna
Treatment-naïve (NEUTRINO) 
Bolesnici koji prethodno nisu bili liječenia (NEUTRINO)
Emtricitabine ↔ Cmax 0.97 (0.88, 1.07) ↔ AUC 0.99 (0.94, 1.05) ↔ Cmin 1.04 (0.98, 1.11) 
↔ Cmax 0,97 (0,88; 1,07) ↔ AUC 0,99 (0,94; 1,05) ↔ Cmin 1,04 (0,98; 1,11)
Musculoskeletal and connective tissue disorders: Very common arthralgia, myalgia 
Vrlo često artralgija, mialgija
PEG+RBV 24 weeks (n = 176) 
PEG+RBV 24 tjedna (n = 176)
SOF+RBV 16 weeks 
SOF+RBV 16 tjedana
GS-331007 ↓ Cmax 0.73c (0.65, 0.83) ↔ AUC 1.04c (0.89, 1.22) Cmin (NA) 
GS­331007 ↓ Cmax 0,73c (0,65; 0,83) ↔ AUC 1,04c (0,89; 1,22) Cmin (ND/NP)
Consideration should be given to treating these patients, and potentially extending the duration of therapy with sofosbuvir, peginterferon alfa and ribavirin beyond 12 weeks and up to 24 weeks; especially for those subgroups who have one or more factors historically associated with lower response rates to interferon-based therapies (prior null response to peginterferon alfa and ribavirin therapy, advanced fibrosis/cirrhosis, high baseline viral concentrations, black race, IL28B non CC genotype). 
Potrebno je razmotriti mogućnost liječenja tih bolesnika i mogućnost produljenja trajanja terapije sofosbuvirom, peginterferonom alfa i ribavirinom na više od 12 tjedana do najviše 24 tjedna, osobito u podskupina s jednim ili više čimbenika koji se otprije povezuju s nižim stopama odgovora na terapiju temeljenu na interferonu (prethodni izostanak odgovora na terapiju peginterferonom alfa i ribavirinom, uznapredovala fibroza/ciroza, visoke početne koncentracije virusa, crna rasa, ne­CC genotip IL28B).
No dose adjustment of sofosbuvir or efavirenz is required when sofosbuvir and efavirenz are used concomitantly. 
Nije potrebna prilagodba doze sofosbuvira ili efavirenza kad se sofosbuvir i efavirenz primjenjuju istodobno.
Dose modification in adolescents Dose reduction of Sovaldi is not recommended. 
Ne preporučuje se smanjenje doze lijeka Sovaldi.
Treatment-experienced patients with genotype 1, 4, 5 and 6 HCV infection 
Prethodno liječeni bolesnici s infekcijom HCV­om genotipa 1, 4, 5 i 6
HIV ANTIVIRAL AGENTS: INTEGRASE INHIBITORS Raltegravirf (400 mg twice daily) 
Raltegravirf (400 mg dvaput na dan)
Refer to the ribavirin prescribing information for guidance on dose modification or discontinuation. 
Pogledajte smjernice za prilagodbu doze ili prekid primjene u informacijama o propisivanju ribavirina.
No dose adjustment of sofosbuvir or methadone is required when sofosbuvir and methadone are used concomitantly. 
Nije potrebna prilagodba doze sofosbuvira ili metadona kad se sofosbuvir i metadon primjenjuju istodobno.
Sofosbuvir was studied in an open-label clinical study evaluating the safety and efficacy of 24 weeks of treatment with sofosbuvir and ribavirin in liver transplant recipients with chronic hepatitis C. Eligible patients were ≥18 years old and had undergone liver transplantation 6 to 150 months prior to screening. 
Sofosbuvir je bio ispitan u otvorenom kliničkom ispitivanju u kojem se ocjenjivala sigurnost i djelotvornost liječenja sofosbuvirom i ribavirinom u trajanju od 24 tjedna u bolesnika s kroničnim hepatitisom C kojima je transplantirana jetra.
Darunavir ↔ Cmax 0.97 (0.94, 1.01) ↔ AUC 0.97 (0.94, 1.00) ↔ Cmin 0.86 (0.78, 0.96) 
↔ Cmax 0,97 (0,94; 1,01) ↔ AUC 0,97 (0,94; 1,00) ↔ Cmin 0,86 (0,78; 0,96)
No dose adjustment of sofosbuvir or emtricitabine is required when sofosbuvir and emtricitabine are used concomitantly. 
Nije potrebna prilagodba doze sofosbuvira ili emtricitabina kad se sofosbuvir i emtricitabin primjenjuju istodobno.
Tenofovir ↑ Cmax 1.25 (1.08, 1.45) ↔ AUC 0.98 (0.91, 1.05) ↔ Cmin 0.99 (0.91, 1.07) 
↑ Cmax 1,25 (1,08; 1,45) ↔ AUC 0,98 (0,91; 1,05) ↔ Cmin 0,99 (0,91; 1,07)
No dose adjustment of sofosbuvir or rilpivirine is required when sofosbuvir and rilpivirine are used concomitantly. 
Nije potrebna prilagodba doze sofosbuvira ili rilpivirina kad se sofosbuvir i rilpivirin primjenjuju istodobno.
Co-administration of Sovaldi with rifapentine is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of Sovaldi. 
Očekuje se da će istodobna primjena Sovaldija s rifapentinom smanjiti koncentraciju sofosbuvira i tako dovesti do smanjenog terapijskog učinka lijeka Sovaldi.
You can also report any side effects directly to the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine. 
Nuspojave možete prijaviti izravno putem nacionalnog sustava za prijavu nuspojava: navedenog u Dodatku V.
• palpitations 
● omaglica
Raltegravir ↓ Cmax 0.57 (0.44, 0.75) ↓ AUC 0.73 (0.59, 0.91) ↔ Cmin 0.95 (0.81, 1.12) 
↓ Cmax 0,57 (0,44; 0,75) ↓ AUC 0,73 (0,59; 0,91) ↔ Cmin 0,95 (0,81; 1,12)
PEG+RBV 24 weeks (n = 243) 
PEG+RBV 24 tjedna (n = 243)
Co-administration of Sovaldi with modafinil is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of Sovaldi. 
Očekuje se da će istodobna primjena Sovaldija s modafinilom smanjiti koncentraciju sofosbuvira i tako dovesti do smanjenog terapijskog učinka Sovaldija.
S-methadone ↔ Cmax 0.95 (0.79, 1.13) ↔ AUC 0.95 (0.77, 1.17) ↔ Cmin 0.95 (0.74, 1.22) 
↔ Cmax 0,95 (0,79; 1,13) ↔ AUC 0,95 (0,77; 1,17) ↔ Cmin 0,95 (0,74; 1,22)
NARCOTIC ANALGESICS Methadonef (Methadone maintenance therapy [30 to 
Metadonf (terapija održavanja metadonom [30 do 130 mg na dan])
Two NS5B substitutions, L159F and V321A, were detected in post-treatment relapse samples from multiple genotype 3 HCV infected patients in the Phase 3 clinical studies. 
U kliničkim ispitivanjima faze 3 su u uzorcima više bolesnika zaraženih genotipom 3 HCV­a s relapsom nakon liječenja bile otkrivene dvije NS5B supstitucije, L159F i V321A.
Sofosbuvir ↓ Cmax 0.23 (0.19, 0.29) ↓ AUC 0.28 (0.24, 0.32) Cmin (NA) 
↓ Cmax 0,23 (0,19; 0,29) ↓ AUC 0,28 (0,24; 0,32) Cmin (ND/NP)
Efavirenz ↔ Cmax 0.95 (0.85, 1.06) ↔ AUC 0.96 (0.91, 1.03) ↔ Cmin 0.96 (0.93, 0.98) 
↔ Cmax 0,95 (0,85; 1,06) ↔ AUC 0,96 (0,91; 1,03) ↔ Cmin 0,96 (0,93; 0,98)
Sofosbuvir ↑ Cmax 1.21 (0.90, 1.62) ↔ AUC 1.09 (0.94, 1.27) Cmin (NA) 
↑ Cmax 1,21 (0,90; 1,62) ↔ AUC 1,09 (0,94; 1,27) Cmin (NA)
Sofosbuvir ↓ Cmax 0.97 (0.65, 1.43) ↑ AUC 1.13 (0.81, 1.57) Cmin (NA) 
↓ Cmax 0,97 (0,65; 1,43) ↑ AUC 1,13 (0,81; 1,57) Cmin (ND/NP)
b. The denominator for relapse is the number of patients with HCV RNA <LLOQ at their last on-treatment assessment. 
b. Nazivnik za relaps je broj bolesnika s HCV RNK < donje granice kvantifikacije na njihovom posljednjem pregledu za vrijeme trajanja terapije.
Treated patients (n = 419) had a median age of 51 years (range: 19 to 74); 60% of the patients were male; median body mass index was 25 kg/m2 (range: 17 to 44 kg/m2); the mean baseline HCV RNA level was 6.4 log10 IU/mL; 21% had cirrhosis; 78% had HCV genotype 3; 65% were prior relapsers. 
Medijan dobi liječenih bolesnika (n = 419) bio je 51 godina (raspon: 19 do 74); 60% bolesnika bili su muškarci; medijan indeksa tjelesne mase iznosio je 25 kg/m2 (raspon: 17 do 44 kg/m2); srednja vrijednost početne razine HCV RNK bila je 6,4 log10 IU/ml; 21% imalo je cirozu; 78% imalo je HCV­genotip 3; 65% je prethodno imalo relaps.
SOF+RBV 16 weeks (n = 98)a 
SOF+RBV 16 tjedana (n = 98)a
Overall Genotype 1a Genotype 1b No cirrhosis Cirrhosis 
Ukupnoc Genotip 1ac Genotip 1bc Bez cirozec
Rilpivirine ↔ Cmax 1.05 (0.97, 1.15) ↔ AUC 1.06 (1.02, 1.09) ↔ Cmin 0.99 (0.94, 1.04) 
↔ Cmax 1,05 (0,97; 1,15) ↔ AUC 1,06 (1,02; 1,09) ↔ Cmin 0,99 (0,94; 1,04)
PEG+RBV 24 weeks (n = 67) 
PEG+RBV 24 tjedna (n = 67)
Adults The recommended dose is one 400 mg tablet, taken orally, once daily with food (see section 5.2). 
Preporučena doza je jedna tableta od 400 mg, koja se uzima peroralno jedanput na dan s hranom
Of the 50 treated patients, the median age was 15 years (range: 12 to 17); 42% of the patients were female; 90% were White, 4% were Black, and 2% were Asian; 4% were Hispanic/Latino; mean body mass index was 22 kg/m2 (range: 16 to 32 kg/m2); 18% were treatment experienced; 66% had baseline HCV RNA levels greater than or equal to 800,000 IU/mL; 74% of patients had non-CC IL28B alleles (CT or TT); and no patients had known cirrhosis. 
U tih 50 liječenih bolesnika, medijan dobi iznosio je 15 godina (raspon: od 12 do 17); 42% bolesnika bile su žene, 90% bili su bijelci, 4% crnci i 2% Azijci; 4% bili su hispano­ ili latino porijekla; srednja vrijednost indeksa tjelesne mase bila je 22 kg/m2 (raspon: od 16 do 32 kg/m2); 18% bilo je prethodno liječeno; 66% imalo je početne razine HCV RNK više ili jednake 800 000 IU/ml; 74% bolesnika imalo je ne­CC IL28B alele (CT ili TT) te nijedan bolesnik nije imao utvrđenu cirozu.
Patients with Renal Impairment 
Bolesnici s oštećenjem bubrega
Table 11: Response rates in study POSITRON 
Tablica 11: Stope odgovora u ispitivanju POSITRON SOF+RBV
Table 18: SVR12 rates for selected subgroups by genotype in study PHOTON-1 
Tablica 18 prikazuje analizu prisutnosti ciroze u podskupinama prema genotipu Tablica 18: Stope SVR12 za odabrane podskupine prema genotipu u ispitivanju PHOTON-1
Co-administration of Sovaldi with oxcarbazepine is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of Sovaldi. 
Očekuje se da će istodobna primjena Sovaldija s okskarbazepinom smanjiti koncentraciju sofosbuvira i tako dovesti do smanjenog terapijskog učinka Sovaldija.
Patients with HCV genotype 2 or 3 infection in the trial were treated with sofosbuvir with ribavirin for 12 or 24 weeks, respectively. 
Bolesnici zaraženi HCV­om genotipa 2 u kliničkom su ispitivanju liječeni sofosbuvirom s ribavirinom tijekom 12 tjedana, a oni zaraženi HCV­om genotipa 3 liječeni su tijekom 24 tjedna.
SOF+RBV 12 weeks (n = 183) 
SOF+RBV 12 tjedana (n = 183)
No dose adjustment of sofosbuvir or tacrolimus is required at initiation of co-administration. 
Nije potrebna prilagodba doze sofosbuvira ili takrolimusa na početku istodobne primjene.
Dialysis 
Doziranje
SOF+RBV 12 weeks 
SOF+RBV 12 tjedana
No dose adjustment of sofosbuvir or tenofovir disoproxil is required when sofosbuvir and tenofovir disoproxil are used concomitantly. 
Nije potrebna prilagodba doze sofosbuvira ili tenofovirdizoproksila kad se sofosbuvir i tenofovirdizoproksil primjenjuju istodobno.
Ciclosporin ↔ Cmax 1.06 (0.94, 1.18) ↔ AUC 0.98 (0.85, 1.14) Cmin (NA) 
↔ Cmax 1,06 (0,94; 1,18) ↔ AUC 0,98 (0,85; 1,14) Cmin (ND/NP)
• fainting 
● nesvjesticu
R-methadone ↔ Cmax 0.99 (0.85, 1.16) ↔ AUC 1.01 (0.85, 1.21) ↔ Cmin 0.94 (0.77, 1.14) 
↔ Cmax 0,99 (0,85; 1,16) ↔ AUC 1,01 (0,85; 1,21) ↔ Cmin 0,94 (0,77; 1,14)
The pharmacokinetic properties of sofosbuvir and the predominant circulating metabolite GS-331007 have been evaluated in healthy adult subjects and in patients with chronic hepatitis C. Following oral administration, sofosbuvir was absorbed quickly and the peak plasma concentration was observed ~0.5-2 hour post-dose, regardless of dose level. 
Farmakokinetička svojstva sofosbuvira i glavnog cirkulirajućeg metabolita GS­331007 ocijenjena su u zdravih odraslih ispitanika i u bolesnika s kroničnim hepatitisom C.
SOF+RBV 12 weeks TN (n = 42) 
SOF+RBV 12 tjedana TN (n = 42)
The safety and efficacy of 12 weeks of treatment with ledipasvir/sofosbuvir in 18 genotype 1 HCV-infected patients with severe renal impairment not requiring dialysis was also studied in Study 0154. 
U ispitivanju 0154 procijenjene su također sigurnost i djelotvornost 12­tjednog liječenja ledipasvirom/sofosbuvirom u 18 bolesnika zaraženih HCV­om genotipa 1 i teškim oštećenjem bubrega koje nije zahtijevalo dijalizu.
SOF+RBV 12 weeks (n = 73)a 
SOF+RBV 12 tjedana (n = 73)a
SOF+RBV 12 weeks TN (n = 26) 
SOF+RBV 12 tjedana TN (n = 26)
Treated patients (n = 278) had a median age of 54 years (range: 21 to 75); 54% of the patients were male; 91% were White; 5% were Black; 11% were Hispanic or Latino; mean body mass index was 28 kg/m2 (range: 18 to 53 kg/m2); 70% had baseline HCV RNA levels greater than 6 log10 IU/mL; 16% had cirrhosis; 49% had HCV genotype 3. 
Medijan dobi liječenih bolesnika (n = 278) bio je 54 godine (raspon: 21 do 75); 54% bolesnika bili su muškarci; 91% bili su bijelci, 5% bili su crnci; 11% bili su hispano­ ili latino­porijekla; srednja vrijednost indeksa tjelesne mase bila je 28 kg/m2 (raspon: 18 to 53 kg/m2); 70% imalo je početne razine HCV RNK veće od 6 log10 IU/ml; 16% imalo je cirozu; 49% imalo je HCV­genotip 3.
• light-headedness 
● ošamućenost
Table 20: Outcomes by therapeutic regimen and treatment duration, a comparison across studies in genotype 1 HCV infection 
Tablica 20: Ishodi prema terapijskom režimu i trajanju liječenja, usporedba ispitivanja za infekciju genotipom 1 HCV­a